Used in targeted cancer therapies, particularly in the development of antibody-drug conjugates (ADCs). It specifically binds to the KAAG1 antigen, which is overexpressed in certain tumor cells, enabling selective delivery of cytotoxic agents directly to cancer cells while minimizing damage to healthy tissues. This antibody serves as a critical tool in preclinical research for validating target engagement and optimizing ADC design. Its high specificity supports applications in immunoassays, flow cytometry, and immunohistochemistry to detect KAAG1 expression in tumor samples, aiding in patient stratification and biomarker development.